Land: Ierland
Taal: Engels
Bron: HPRA (Health Products Regulatory Authority)
Triclabendazole
Cross Vetpharm Group Limited
QP52AC01
Triclabendazole
100 milligram(s)/millilitre
Oral suspension
LM: Licensed Merchant as defined in relevant national legislation
Cattle, Sheep
triclabendazole
Endoparasiticide
Authorised
2002-08-01
Health Products Regulatory Authority 03 May 2019 CRN0091QM Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Endofluke 100 mg/ml Oral Suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance per ml Triclabendazole 100 mg Excipients Methyl Parahydroxybenzoate (E218) 2 mg (preservative) Propyl Parahydroxybenzoate (E216) 0.2 mg (preservative) For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Oral Suspension. A white to off-white suspension. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle & Sheep 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of adult, immature and early immature stages of liver fluke (_Fasciola hepatica_) susceptible to triclabendazole. 4.3 CONTRAINDICATIONS Do not use in animals known to be hypersensitive to the active substance. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Care should be taken to avoid the following practices, because they increase the risk of development of resistance and could ultimately result in ineffective therapy: - Too frequent and repeated use of anthelmintics from the same class, over an extended period of time. - Under dosing, which may be due to under estimation of bodyweight, misadministration of the product or lack of calibration of the dosing device (if any). Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used. Resistance to triclabendazole has been reported in _Fasciola hepatica _in cattle and sheep. Therefore, the use of this product should be based on local (regional/farm) epidemiological information about susceptibility of the _Fasciola hepatica _and recommendations on how to limit further selection for resistance to anthelmintics. Health Products Regulatory Authority Lees het volledige document